Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Navitas’ GaN & SiC Devices Power Dell’s™ Family of AI Notebooks
-
Montgomery County ADAMHS Conducts First-Ever Online Auction for 19 Acre Property on GovDeals
-
SFL - Invitation to Presentation of Q4 2024 Results
-
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development
-
Cyabra Launches AI-Powered 'Insights' Feature, Safeguarding Brands and Governments Against AI-Driven Digital Disinformation
-
Cyabra Launches AI-Powered 'Insights' Feature, Safeguarding Brands and Governments Against AI-Driven Digital Disinformation
-
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
-
Oxbridge / SurancePlus Selects Coinbase Prime to Support Strategic Bitcoin and Ethereum Investment
-
A Race Against Blindness Announces $2 Million Grant to Support Sight-Saving Clinical Trial
-
Form 8.3 - Learning Technologies Group plc - Octopus Investments
-
Form 8.3 - [LEARNING TECHNOLOGIES GROUP PLC - 04 02 2025] - (CGWL)
-
Ensemble Receives Fifth Best in KLAS Designation for Delivering Frictionless Revenue Cycle and Exceptional Patient Experiences
-
Form 8.3 - [ALLIANCE PHARMA PLC - 04 02 2025] - (CGWL)
-
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
Aspire North Launches Aspire Data Network Utilizing Experian Marketing Data
-
Stellantis to Announce Full Year 2024 Results on February 26
-
Qsic Names In-Store Retail Media Leader Marc Walkin as Vice President of Marketing
-
How Athletic Brewing Optimized Logistics and Cut Costs with ShipperGuide TMS and Opendock
-
New Hope For Pets In The Fight Against Cancer: Fast, Accurate Diagnoses From Torigen Pharmaceuticals And Proscia
-
ITW Reports Fourth Quarter and Full Year 2024 Results
-
Stryker declares an $0.84 per share quarterly dividend
-
The Challenges for Neurodiverse Students in Post-Secondary Education
-
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
Twin Disc Approves a Quarterly Cash Dividend
-
Asia Broadband’s Nears Completion Of Its Next-Generation AABB Wallet’s On/Off Ramp To Facilitate Users to Buy and Sell the AABBG Token
-
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
-
CloudCasa Expands OpenShift Protection with Full Support for OpenShift Virtualization Engine
-
UNIQ Supply Expands to Support America’s Food & Beverage Entrepreneurs
-
Twin Disc Announces Second Quarter Results
-
Mitolyn Unveils Innovative Formula and Complete Ingredients Benefits
-
Eric Herzog Named a CRN Channel Chief for the Third Time
-
AquaSculpt Publishes Full Natural Ingredients List to Offer Customers Full Transparency and Confidence
-
Fast Food Operator Enhances Safety while Reducing Costs with Interface Virtual Guard
-
Scality appoints Emilio Roman as global chief revenue officer
-
Intelerad Earns 2025 Best in KLAS Award for InSight PACS in the UK and Ireland
-
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
Willis appoints Stephen Kyriacou Head of Litigation and Contingent Risk Solutions in North America
-
Rezolve Ai Kicks Off 2025 with Major Retail Expansion as Leading Brands Leverage Its Cutting-Edge Technology
-
Alice Group USA Announces Acquisition Strategy and Transformation of TFLM
-
Algorhythm Holdings Announces Date and Ratio of Reverse Stock Split
-
Music of Your Life Gears Up for Milestone 50th Anniversary Celebration
-
Oxbridge / SurancePlus Selects Coinbase Prime to Support Strategic Investments in Digital Assets
-
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
-
Xsolis Ranked No. 1 Best in KLAS for Physician Advisory Services for Fourth Year
-
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
-
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
-
WillScot to Announce Fourth Quarter 2024 Results on February 20, 2025
-
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
-
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
